{
  "asset": "IMBRUVICA (ibrutinib)",
  "query_terms": [
    "IMBRUVICA (ibrutinib)",
    "ibrutinib",
    "IMBRUVICA"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT04010968",
      "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia: a Randomized Phase II Trial Comparing FCR and a Chemo-free Combination of Venetoclax and Ibrutinib. A FILO Study",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Intermediate Risk Chronic Lymphocytic Leukemia",
        "Fit Patients",
        "Risk-Adapted and MRD-Driven Strategy"
      ],
      "lead_sponsor": "French Innovative Leukemia Organisation",
      "collaborators": [
        "AbbVie",
        "Janssen-Cilag Ltd."
      ],
      "interventions": [
        "venetoclax and ibrutinib (I+VEN)",
        "FCR"
      ],
      "last_update": "2025-11-26",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04010968"
    },
    {
      "nct_id": "NCT02315326",
      "title": "A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)",
        "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"
      ],
      "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
      "collaborators": [
        "Pharmacyclics LLC.",
        "Janssen Biotech, Inc."
      ],
      "interventions": [
        "Ibrutinib",
        "HD- Methotrexate (MTX)",
        "Rituximab + HD- Methotrexate (MTX)",
        "procarbazine"
      ],
      "last_update": "2025-07-01",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02315326"
    },
    {
      "nct_id": "NCT02824159",
      "title": "Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment.",
      "overall_status": "COMPLETED",
      "phase": null,
      "conditions": [
        "Hematological Malignancies"
      ],
      "lead_sponsor": "University Hospital, Toulouse",
      "collaborators": [],
      "interventions": [
        "Blood samples for pharmacokinetics exploration",
        "Imagery",
        "Quality of life scale",
        "Detection of adverse events",
        "Saliva samples",
        "Blood sample",
        "Biological statement",
        "Clinical examination"
      ],
      "last_update": "2020-12-28",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02824159"
    },
    {
      "nct_id": "NCT03447808",
      "title": "Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "lead_sponsor": "Jennifer Woyach",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Ibrutinib",
        "Laboratory Biomarker Analysis",
        "Pharmacological Study"
      ],
      "last_update": "2026-01-07",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03447808"
    },
    {
      "nct_id": "NCT06649812",
      "title": "A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type"
      ],
      "lead_sponsor": "National Cancer Institute (NCI)",
      "collaborators": [],
      "interventions": [
        "Biopsy Procedure",
        "Biospecimen Collection",
        "Bone Marrow Aspiration",
        "Bone Marrow Biopsy",
        "Computed Tomography",
        "Ibrutinib",
        "Lenalidomide",
        "Magnetic Resonance Imaging",
        "Obinutuzumab",
        "Positron Emission Tomography"
      ],
      "last_update": "2025-12-30",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06649812"
    },
    {
      "nct_id": "NCT03478514",
      "title": "A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Mantle Cell Lymphoma",
        "B Cell Lymphoma"
      ],
      "lead_sponsor": "Alliance Foundation Trials, LLC.",
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Palbociclib",
        "Ibrutinib"
      ],
      "last_update": "2025-12-18",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03478514"
    },
    {
      "nct_id": "NCT02827617",
      "title": "Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "phase": null,
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "lead_sponsor": "Oncology Institute of Southern Switzerland",
      "collaborators": [],
      "interventions": [
        "Ibrutinib"
      ],
      "last_update": "2025-11-18",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02827617"
    },
    {
      "nct_id": "NCT02420912",
      "title": "Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Loss of Chromosome 17p",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma",
        "Richter Syndrome"
      ],
      "lead_sponsor": "M.D. Anderson Cancer Center",
      "collaborators": [
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Ibrutinib",
        "Laboratory Biomarker Analysis",
        "Nivolumab"
      ],
      "last_update": "2024-03-20",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02420912"
    },
    {
      "nct_id": "NCT02824029",
      "title": "A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Classical Hodgkin Lymphoma",
        "Recurrent Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma"
      ],
      "lead_sponsor": "Barbara Ann Karmanos Cancer Institute",
      "collaborators": [
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Ibrutinib",
        "Laboratory Biomarker Analysis",
        "Pharmacological Study"
      ],
      "last_update": "2025-02-17",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02824029"
    },
    {
      "nct_id": "NCT02514083",
      "title": "A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "lead_sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "collaborators": [],
      "interventions": [
        "Ibrutinib",
        "Fludarabine"
      ],
      "last_update": "2024-09-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02514083"
    }
  ]
}